Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus

Fig. 2

All-cause mortality among patients with metformin vs. placebo; and combination vs. placebo. Metformin treatment has no meaningful impact on all-cause mortality versus control, with a moderate heterogeneity. When used in conjunction with another antidiabetic drug, it significantly increased the all-cause mortality risk, compared to the antidiabetic drug alone

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840